Other

Csl Limited

The University of New South Wales

Stuart L Hazell

Christopher Vincent Doidge

Adrian Lee

Flona J Radcliff

Elizabeth Ann Webb

Linda J Rothel

Phillip Sutton

Fona J Radcliff

An isolated polypeptide and immunogenic fragments thereof are described together with their variants and derivatives as novel immunogenic agents for treating or preventinginfection in a mammalian host. The polypeptide comprises a C-terminal portion of acatalase, which portion lacks significant amino acid sequence identity with human catalase, wherein the polypeptide is other than full-lengthcatalase.

Polypeptide fragments comprising c terminal portion of helicobacter catalase

An antigenic preparation for use in the treatment or prevention of Helicobacter infection in a mammalian host, comprises the catalase enzyme of Helicobacter bacteria, particularly the catalase enzyme of or , or an immunogenic fragment thereof.

Treatment and prevention of helicobacter infection

An antigenic preparation for use in the treatment of prevention of Helicobacter infection in a mammalian host, comprises the catalase enzyme of Helicobacter bacterial, particularly the catalase enzyme of or , or an immunogenic fragment thereof.

An antigenic preparation for use in the treatment or prevention of Helicobacter infection in a mammalian host, comprises the catalase enzyme of Helicobacter bacteria, particularly the catalase enzyme of H. pylori or H. felis, or an immunogenic fragment thereof.

Growing community of inventors

Glenfield, Australia

Stuart L Hazell